Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity

Summary

A Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male and female participants at least 18 years of age who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) who have at least 1 weight-related comorbidity

Timeline

Start

2024-10-08

Primary completion

2025-11-21

Completion

2025-11-21

Publications

• Davies MJ, Aroda VR, Rosenstock J, Capehorn M, Pedersen SD, Morizzo E, Malhotra S, Johansson PA, Grice D, Andersson A, Rizi EP, Sjostrom CD. Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial. Lancet. 2026 Jun 20;407(10547):2503-2514. doi: 10.1016/S0140-6736(26)00748-8. Epub 2026 Jun 8.

Drugs

Indications